Whitehawk Therapeutics Stock (NASDAQ: WHWK)

Dernières nouvelles pour Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics Inc

Barclays analyst Alex Scott downgrades Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Overweight to Equal-Weight and lowers the price target from $280 to $274.

News

Downgrades

Price Target

Analyst Ratings

Barclays Downgrades Travelers Companies to Equal-Weight, Lowers Price Target to $274

Securities to be Purchased by Heights Capital Management, Inc.; Common Stock and Pre-Funded Warrants Sold at $55.49 per Share and Warrants at $99.88 Exercise Price
Investment Demonstrates IonQ's Unique Position in Commercial Quantum Computing and Networking
IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) ("IonQ" or the "Company"), a leading commercial quantum computing and networking company, today announced the pricing of a $1.0 billion equity offering consisting of 14,165,708 shares of IonQ's common stock, each at $55.49 per share, and pre-funded warrants to purchase 3,855,557 shares of IonQ's common stock, each at $55.49 per pre-funded warrant, each representing a premium of about 25% to IonQ's closing stock price on July 3, 2025, as well as seven-year warrants to purchase 36,042,530 additional shares of IonQ's common stock, for no additional consideration, at an exercise price of $99.88 per share. The securities offered will be purchased from the underwriter by Heights Capital Management, Inc. (the "investor").
Niccolo de Masi, President and CEO, of IonQ said, "IonQ is well-capitalized with a strong cash position and has been rapidly expanding our ecosystem as we execute against our global quantum computing and networking strategy. We believe this is the largest common-stock single-institutional investment in the history of the quantum industry. It is a tremendous validation of our technical momentum, recent acquisitions, IP, and talent density. With this transaction, IonQ will benefit from a balance sheet of approximately $1.68 billion of pro-forma cash as of March 31, 2025, underwriting our sustained growth and pioneering quantum commercialization worldwide."
J.P. Morgan acted as the sole underwriter in the transaction. Paul, Weiss, Rifkind, Wharton &amp; Garrison LLP served as legal counsel to IonQ. Simpson Thacher &amp; Bartlett LLP acted as legal counsel to J.P. Morgan. Skadden, Arps, Slate, Meagher &amp; Flom LLP acted as legal counsel to the investor.

Offerings

IONQ

IonQ Prices $1 Billion Equity Offering Of ~14.17M Shares And ~3.86M Pre-Funded Warrants At $55.49 Each; As Well As, ~36M 7-Year Warrants At $99.88 Exercise Price Purchased By Heights Capital Management

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Gastrointestinal Cancers Congress (ESMO-GI) in Barcelona, Spain, along with regulatory updates from its July 1, 2025 End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA).

AGEN

Agenus Says BOT/BAL Combination Achieves 2-Yr Survival Rate Of 42% Along With Now More Mature 21-Month Median OS In Expanded Cohort Of 123 Patients With MSS mCRC Without Active Liver Metastases

Barclays analyst Ramsey El-Assal initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Overweight rating and announces Price Target of $40.

Initiation

CHYM

Barclays Initiates Coverage On Chime Financial with Overweight Rating, Announces Price Target of $40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan raised Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) price target from $25 to $35. JP Morgan analyst Ekaterina Knyazkova upgraded the stock from Neutral to Overweight. Phibro Animal Health shares closed at $28.00 on Thursday. See how other analysts view this stock.</li>
<li>Jefferies cut the price target for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from $53 to $42. Jefferies analyst Surinder Thind downgraded the stock from Hold to Underperform. ASGN shares closed at $52.84 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) price target from $51 to $57. Raymond James analyst Michael Rose upgraded the stock from Outperform to Strong Buy. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from $194 to $205. Jefferies analyst Kaumil Gajrawala upgraded the stock from Hold to Buy. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased the price target for MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) from $32 to $33. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. MP Materials shares closed at $31.84 on Thursday. <a href="https://www.benzinga.com/quote/MP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $4.9 to $7.2. Jefferies analyst Julien Dumoulin-Smith upgraded the stock from Hold to Buy. Shoals Technologies shares settled at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) price target from $16.5 to $11.75. B of A Securities analyst Michael Jacks downgraded the stock from Buy to Neutral&nbsp;. Stellantis shares closed at $10.31 on Thursday. <a href="https://www.benzinga.com/quote/STLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $150 to $175. B of A Securities analyst Koji Ikeda maintained a Buy rating. Datadog shares closed at $155.15 on Thursday.  <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from $321 to $298. Barclays analyst Alex Scott downgraded the stock from Overweight to Equal-Weight. Chubb shares settled at $283.80 on Thursday. <a href="https://www.benzinga.com/quote/CB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised XPO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NASDAQ">XPO</a>) price target from $139 to $150. B of A Securities analyst Ken Hoexter maintained a Buy rating. XPO shares closed at $132.13 on Thursday. <a href="https://www.benzinga.com/quote/XPO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying USB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/USB/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png" alt="" class="wp-image-974719" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

ASGN

DDOG

DKNG

NVDA

PAHC

SHLS

STLA

U.S. Bancorp To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Inspira&#x2122; Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework.
The meeting, scheduled for July 8, 2025, is intended to define the key terms and roadmap for this strategic collaboration. These advanced discussions were initiated following a direct invitation from the government of the health authority, which is actively seeking to secure next-generation medical technologies and enhance national emergency readiness.
The government involved is recognized for its extensive commercial ties and diplomatic channels spanning the entire international community. Accordingly, the agenda will also feature the discussion relating to the establishment of a global distribution framework that leverages these unique capabilities with the aim to accelerate and increase the profitability of the $22.5 million purchase order received by Inspira, as announced on July 2, 2025.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies In Talks With Government Health Authority To Advance National Integration Of FDA-Cleared ART100 System And To Establish Global Distribution Framework

LRHC

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">June 2025 Bitcoin Mining Updates (unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Key Metrics</td>
<td colspan="1" rowspan="1">Results (Rounded Numbers)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoins Mined During the Month</td>
<td colspan="1" rowspan="1">88 Bitcoins</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Bitcoins Owned by Canaan Inc. on Balance Sheet[1]</td>
<td colspan="1" rowspan="1">1,484 Bitcoins</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Deployed Hashrate (EH/s)</td>
<td colspan="1" rowspan="1">8.15 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Operating Hashrate (EH/s)</td>
<td colspan="1" rowspan="1">6.57 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Average Revenue Split[2]</td>
<td colspan="1" rowspan="1">62.3&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average All-in Power Cost During the Month[3]</td>
<td colspan="1" rowspan="1">US$0.045/kWh</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4" rowspan="1">June 2025 Bitcoin Mining Infrastructure Updates (unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">North America</td>
<td colspan="1" rowspan="1">Non-North America</td>
<td colspan="1" rowspan="1">Global</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Average Miner Efficiency</td>
<td colspan="1" rowspan="1">20.1 J/TH</td>
<td colspan="1" rowspan="1">29.7 J/TH</td>
<td colspan="1" rowspan="1">26.3 J/TH</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Installed Power Capacity</td>
<td colspan="1" rowspan="1">76.3 MW</td>
<td colspan="1" rowspan="1">139.6 MW</td>
<td colspan="1" rowspan="1">216.0 MW</td>
</tr>
</tbody>
</table>
</figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Canaan Provides June 2025 Bitcoin Production And Mining Operation Updates; 88 Bitcoins Mined During The Month

Evercore ISI Group analyst Steve Sakwa upgrades UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) from In-Line to Outperform and raises the price target from $45 to $46.

Upgrades

Evercore ISI Group Upgrades UDR to Outperform, Raises Price Target to $46

Second Quarter Expectations and Revised Guidance
The Company expects net income in the range of $45 million to $55 million and adjusted EBITDA of approximately $135 million this quarter relative to its prior adjusted EBITDA guidance range of $120 million to $125 million. The Company has also increased its full year 2025 adjusted EBITDA guidance to a range of $530 million to $550 million from its original range of $520 million to $540 million.

Guidance

Element Solutions Raises Q2 Net Income Guidance To $45M-$55M And Adjusted EBITDA To ~$135M; Full-Year 2025 Adjusted EBITDA Forecast Increased From $520M-$540M To $530M-$550M

Barclays analyst Alex Scott initiates coverage on Ategrity Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIC#NYSE">ASIC</a>) with a Overweight rating and announces Price Target of $30.

ASIC

Barclays Initiates Coverage On Ategrity Specialty with Overweight Rating, Announces Price Target of $30

B of A Securities analyst Ken Hoexter maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $139 to $150.

B of A Securities Maintains Buy on XPO, Raises Price Target to $150

Barclays analyst Alex Scott downgrades Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from Overweight to Equal-Weight and lowers the price target from $321 to $298.

Barclays Downgrades Chubb to Equal-Weight, Lowers Price Target to $298

WIIM

ALLT

Allot shares are trading higher after the company announced it secured a multi-million dollar deal to boost cybersecurity for a tier 1 EMEA telecom operator.

The United States is bracing for a potential acceleration in inflation, with a significant depreciation of the dollar now identified as a key contributing factor, according to a new analysis by Torsten Sløk, the chief economist at Apollo.
What Happened: As per Sløk&#8217;s <a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/">analysis</a>, a 10% depreciation in the U.S. dollar is projected to boost inflation by 0.3 percentage points.
This comes at a time when inflationary pressures are already building from multiple fronts, including ongoing tariffs, rising oil prices, and existing immigration restrictions.
Sløk emphasizes that &#8220;The bottom line is that we should see inflation move higher over the coming months; that is what the consensus expects, what the Fed expects, and what we expect.&#8221;
As the U.S. Dollar Index Spot has already declined by 10.29% on a year-to-date basis, a chart tracking the &#8220;Shock to Inflation, compared with consensus forecast&#8221; illustrates the projected impact.
A 10% depreciation occurring in the first half of a year (H1) shows a noticeable upward bump to inflation, as does a 10% depreciation in the second half (H2).
The chart also details the impact on U.S. CPI from both a 10% and a 20% depreciation in the dollar, relative to baseline forecasts, stretching from the first quarter of 2025 through the fourth quarter of 2027.
<figure class="wp-block-image size-large"><a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png" alt="" class="wp-image-974689" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart.png 1435w" sizes="(max-width: 1024px) 100vw, 1024px" /></a><figcaption class="wp-element-caption">Source: Apollo Academy</figcaption></figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a>
Why It Matters: During a discussion with Blomberg Television, Sløk was asked about the business environment being stronger than consensus expectations in terms of hiring, without the inflationary impulse.
He said, &#8220;That brings us back to a discussion around what are the effects of the trade war? Are tariffs not going to have an impact? So far, it&#8217;s remarkable, where you have inflation still steady, and now the job growth still strong. So in that sense, there is literally very little sign of the trade war having a macroeconomic impact at this point.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Torsten Slok, chief economist at Apollo, reacts to the June US jobs report, which saw the unemployment rate move down to 4.1% with job growth that exceeded expectations for a fourth straight month <a href="https://t.co/ucnIBVQGMM">https://t.co/ucnIBVQGMM</a> <a href="https://t.co/VOhBqK7ZQY">pic.twitter.com/VOhBqK7ZQY</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1940780912268001439?ref_src=twsrc%5Etfw">July 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The U.S. Dollar Index Spot was up 0.19% at the 97.3660 level during the publication of this article.
While, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.13% at $624.54, while the QQQ declined 0.25% to $554.81, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus </a></li>
</ul>
Image via Shutterstock

As US Dollar Sinks, Top Economist Warns 10% Slide Could Spark New Inflation Spike

Barclays analyst Betty Jiang initiates coverage on EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight rating and announces Price Target of $65.

Barclays Initiates Coverage On EQT with Overweight Rating, Announces Price Target of $65

White Mountains Insurance Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTM#NYSE">WTM</a>) announced today that it has entered into an agreement to acquire a majority stake in Distinguished Programs ("Distinguished" or the "Company"), an MGA and program administrator for specialty property &amp; casualty insurance. Following the acquisition, White Mountains will own a 51% controlling interest in Distinguished.
Distinguished is an MGA and program manager placing in excess of $550 million in premiums annually across a diversified portfolio of 12 specialty property and casualty programs such as commercial real estate, hotels &amp; restaurants, community associations, environmental &amp; construction professional, cyber, surety, executive lines, inland marine and fine arts &amp; collectibles. Distinguished is led by industry veterans Bill&nbsp;Malloy, Jason Rotman and Steve Sitterly.
Aquiline Capital Partners, the current controlling equityholder of Distinguished, will remain a significant minority equityholder going forward. Distinguished's current executive management team will continue to lead the business, and each will remain a significant equityholder.
&nbsp;
In the transaction, White Mountains will acquire approximately 50% of Distinguished's outstanding equity interests for $230 million. White Mountains currently owns approximately 1% of Distinguished's outstanding equity interests. The transaction is expected to close in the third quarter of 2025. The closing is subject to regulatory approvals and other customary closing conditions.&nbsp;

White Mountains Insurance Group To Acquire 51% Stake In Distinguished Programs, Will Acquire ~50% Of Distinguished's Outstanding Equity Interests For $230M

B of A Securities analyst Koji Ikeda maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $175.

Comments

Whitehawk Therapeutics

Actualités

Dernières nouvelles pour Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL